LENZ Therapeutics (LENZ) Gross Margin (2026)
LENZ Therapeutics (LENZ) posted quarterly Gross Margin of 43.4% for Q1 2026.
LENZ Therapeutics (LENZ) Gross Margin (2026) Analysis & Trends
LENZ Therapeutics (LENZ) has reported Gross Margin for 1 consecutive years, with 43.4% the latest figure, recorded in Q1 2026.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Gross Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 85.33% |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 91.59% |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 90.43% |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 35.86% |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 89.76% |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 76.90% |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 84.20% |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | - |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 63.27% |
| 10 | LENZ Therapeutics | 146.20 Mn | 146.20 Mn | 5.21 Mn | 94.90% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 94.90% |
| Mar 31, 2026 | 43.40% |